Stay updated with breaking news from Nasdaq Clrb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com began coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a research note issued to investors on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Cellectar Biosciences Stock Performance Shares of NASDAQ CLRB opened at $2.78 on Friday. Cellectar Biosciences has a fifty-two week low of $1.25 […]
StockNews.com initiated coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a research note released on Saturday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Cellectar Biosciences Trading Up 1.8 % NASDAQ CLRB traded up $0.05 during trading hours on Friday, reaching $2.90. 105,125 shares of the company’s stock traded […]
StockNews.com began coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a research report report published on Friday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Cellectar Biosciences Stock Up 3.9 % NASDAQ:CLRB opened at $2.64 on Friday. Cellectar Biosciences has a one year low of $1.25 and a […]
StockNews.com assumed coverage on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a report issued on Thursday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Cellectar Biosciences Stock Up 14.6 % Shares of NASDAQ:CLRB opened at $2.51 on Thursday. Cellectar Biosciences has a twelve month low of $1.25 and a […]
The EMA’s PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without...